ALLOGENE THERAPEUTICS, INC. |
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
| 2.875 USD | -0.86% |
|
0.00% | -9.35% |
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Last Days!
Take advantage of the offer
* See conditions on site
Financials (USD)
| Sales 2024 * | 45.6K | Sales 2025 * | 4.75M | Capitalization | 495M |
|---|---|---|---|---|---|
| Net income 2024 * | -288M | Net income 2025 * | -306M | EV / Sales 2024 * | 10,857 x |
| Net cash position 2024 * | - | Net cash position 2025 * | - | EV / Sales 2025 * | 104 x |
| P/E ratio 2024 * |
-1.74
x | P/E ratio 2025 * |
-1.73
x | Employees | 233 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 68.22% |
More Fundamentals
* Assessed data
More news
Latest transcript on Allogene Therapeutics, Inc.
More recommendations
More press releases
More news
| 1 day | -0.17% | ||
| 1 week | +5.15% | ||
| Current month | +10.87% | ||
| 1 month | -13.80% | ||
| 3 months | -37.55% | ||
| 6 months | +15.47% | ||
| Current year | -4.67% |
1 week
2.74
3.65
1 month
2.703.88
Current year
2.615.78
1 year
2.236.89
3 years
2.2331.77
5 years
2.2355.00
10 years
2.2355.00
| Managers | Title | Age | Since |
|---|---|---|---|
Joshua Kazam
FOU | Founder | 47 | 17-10-31 |
David Chang
FOU | Founder | 64 | 18-03-31 |
Geoffrey Parker
DFI | Director of Finance/CFO | 59 | 23-10-15 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
David Bonderman
BRD | Director/Board Member | 81 | 18-04-30 |
Joshua Kazam
FOU | Founder | 47 | 17-10-31 |
Arie Belldegrun
FOU | Founder | 74 | 17-10-31 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 3.54% | 2 M€ | -25.75% | ||
| 0.08% | 0 M€ | 0.00% | - | |
| 0.06% | 2 M€ | -.--% |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-05-14 | 2.88 | -0.69% | 4 460 336 |
| 24-05-13 | 2.9 | +5.07% | 1,163,373 |
| 24-05-10 | 2.76 | -3.50% | 1,020,780 |
| 24-05-09 | 2.86 | +3.62% | 1,140,704 |
| 24-05-08 | 2.76 | -5.15% | 1,141,019 |
Delayed Quote Nasdaq, May 14, 2024 at 09:52 am EDT
More quotes
Allogene Therapeutics, Inc. is a clinical-stage immuno-oncology company. The Company is focused on development of genetically engineered allogeneic T cell product candidates for the treatment of cancer and autoimmune diseases. It is focused on four core programs: Large B-Cell Lymphoma (LBCL), Chronic Lymphocytic Leukemia (CLL), Autoimmune Disease and Renal Cell Carcinoma. It is developing a pipeline of multiple allogeneic chimeric antigen receptor (CAR) T cell product candidates utilizing protein engineering, gene editing, gene insertion and advanced proprietary T cell manufacturing technologies. Its product candidate, cemacabtagene ansegedleucel, referred to as cema-cel, is an engineered allogeneic CAR T cell product candidate that targets CD19, a protein expressed on the cell surface of B cells and a validated target for B cell driven hematological malignancies. It is focused on developing cema-cel for LBCL and CLL. Its pipeline also includes ALLO-316, ALLO-329 and ALLO-647.
Calendar
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
B-
Sell
Buy
Mean consensus
BUY
Number of Analysts
17
Last Close Price
2.9
USD
Average target price
9.536
USD
Spread / Average Target
+228.84%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -4.67% | 495M | |
| +4.81% | 111B | |
| +10.93% | 105B | |
| -12.26% | 22.34B | |
| -2.97% | 21.93B | |
| -5.85% | 18.59B | |
| -36.52% | 18.12B | |
| -9.77% | 16.96B | |
| +3.48% | 13.7B | |
| +37.17% | 12.45B |
- Stock Market
- Equities
- ALLO Stock